$DRVN

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Driven Brands Hldgs (NASDAQ:DRVN), Jasper Therapeutics (NASDAQ:JSPR)

NEW YORK, Nov. 22, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors Driven Brands Holdings, Inc. ( NASDAQ:DRVN ) and Jasper Therapeutics, Inc ( NASDAQ:JSPR ) on behalf of long-term ...

Original reporting
Benzinga · Globe Newswire
Published Nov 23, 2025, 4:49 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 23, 2025, 5:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - Driven Brands Hldgs (NASDAQ:DRVN), Jasper Therapeutics (NASDAQ:JSPR) — source image
Decision brief

The 30-second read

$DRVNNeutralLow
01

Why it matters

Such investigations can lead to short-term stock price volatility but may not affect long-term fundamentals unless allegations are substantiated.

02

Market read

The news is relevant primarily to investors holding positions in DRVN and JSPR, with limited broader market impact.

03

What to watch

Potential positive developments or disclosures could mitigate concerns; market reaction may be muted if investigation results are favorable.

Timing: Immediate; news published on 2025-11-23

Background

The law firm Bragar Eagel & Squire is investigating certain officers and directors of Driven Brands and Jasper Therapeutics, possibly due to concerns over corporate governance or misconduct.

Company-level read

Ticker impact

$DRVNNeutralMedium confidence
Context

High relevance due to ongoing investigation involving company officers and directors.

Expected impact

Potential short-term decline of 3-5% if news leads to negative investor sentiment; long-term impact uncertain.

Evidence & confidence

Investigations can cause short-term uncertainty but may not affect fundamentals unless misconduct is confirmed.

$JSPRNeutralMedium confidence
Context

Moderate relevance; Jasper Therapeutics is involved in the investigation, but the news impact is less direct.

Expected impact

Possible minor fluctuation within ±2% in the short term.

Evidence & confidence

Limited direct impact; market perception may vary based on investigation developments.

Market effects

Potentially negative sentiment in the automotive services and biotech sectors due to governance concerns.

Limited regional impact; news pertains mainly to US-listed companies.

Minimal; specific to US companies.

Counterpoint

The investigation may be a temporary distraction with limited long-term impact, and the companies could recover if no misconduct is found.

Key entities

  • Driven Brands Holdings, Inc.

    A provider of automotive services listed on NASDAQ.

  • Jasper Therapeutics, Inc.

    A biotech company specializing in hematopoietic stem cell therapies.

Related articles

$JSPRMed

Jasper Therapeutics beats Q2 expectations but shares fall after results

Jasper Therapeutics (NASDAQ:JSPR) reported Q2 2026 adjusted loss of $0.10 per share, better than the $0.28 consensus, and a net loss of $2.8 million. Shares fell 4.24% pre-market. In July, Jasper completed an all-stock acquisition of Kira Pharmaceuticals and a $132 million private placement, extending its funding runway into 2H 2028. Pipeline updates include KP-104 Phase 2 interim data in Q4 2026 and briquilimab and KP-701 milestones in early 2027.

$JSPRMed

Jasper Therapeutics, Inc. (JSPR): Results of Operations and Financial Condition

Jasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030204901ex99-1.htm PRESS RELEASE, DATED AUGUST 14, 2026 Exhibit 99.1 Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio

$JSPRMedAI 8/10

Jasper Therapeutics Secures $132M In Financing; Advances Post-Kira Clinical Pipeline

Jasper Therapeutics (JSPR) reported Q2 2026 results and a corporate update after completing its all-stock acquisition of Kira Pharmaceuticals on July 16, 2026. The company raised about $132M via a private placement of non-voting convertible preferred stock. Cash was $7.3M at June 30. Net loss was $2.8M. Pipeline updates include KP-104, briquilimab, and KP-701.

$DRVNMedAI 8/10

Driven Brands (DRVN) Q2 2026 Earnings Call Transcript

Driven Brands (DRVN) reported Q2 2026 revenue of $507.4 million (+6.8%) and system-wide sales of $1.6 billion (+4.9%). Net income from continuing operations was $37.3 million ($0.23 diluted). Adjusted EBITDA was $107 million and adjusted EPS $0.29. Full-year 2026 guidance: revenue $1.95-$2.05B, adjusted EBITDA $430-$460M, free cash flow $125-$145M; net leverage 3.1x.

$DRVNMed

Driven Brands Holdings Inc. (DRVN): Results of Operations and Financial Condition

Driven Brands Holdings Inc. (DRVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningsrelease.htm EX-99.1 Document Driven Brands Holdings Inc. Reports Second Quarter 2026 Results --Revenue increases 6.8% to $507.4 million with same store sales growth of 1.4%-- --Take 5 same store sales increase 3.6%; 24th consecutive quarter of growth-- --N